Literature DB >> 21957154

Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model.

T R Kannan1, Jacqueline J Coalson, Marianna Cagle, Oxana Musatovova, R Doug Hardy, Joel B Baseman.   

Abstract

Mice were infected with Mycoplasma pneumoniae and monitored for the synthesis and distribution of the unique adenosine diphosphate-ribosylating and vacuolating Community Acquired Respiratory Distress Syndrome (CARDS) toxin in bronchiolar lavage fluid (BALF) and lung. We noted direct relationships between the concentration of CARDS toxin and numbers of mycoplasma genomes in BALF and the degree of histologic pulmonary inflammation. Immunostaining of lungs revealed extensive colonization by mycoplasmas, including the detection of CARDS toxin in the corresponding inflamed airways. Lung lesion scores were higher during the early stages of infection, decreased gradually by day 14 postinfection, and reached substantially lower values at day 35. Infected mouse immunoglobulin (Ig) M and IgG titers were positive for CARDS toxin as well as for the major adhesin P1 of M. pneumoniae. These data reinforce the proposed pathogenic role of CARDS toxin in M. pneumoniae-mediated pathologies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21957154      PMCID: PMC3222103          DOI: 10.1093/infdis/jir557

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model.

Authors:  R J Martin; H W Chu; J M Honour; R J Harbeck
Journal:  Am J Respir Cell Mol Biol       Date:  2001-05       Impact factor: 6.914

2.  Mycoplasma pneumoniae-associated Stevens-Johnson syndrome exhibits lymphopenia and redistribution of CD4+ T cells.

Authors:  Lin Wang; Kuo-Ching Hong; Fu-Chein Lin; Kuender D Yang
Journal:  J Formos Med Assoc       Date:  2003-01       Impact factor: 3.282

3.  Rapid detection of Mycoplasma pneumoniae in clinical samples by real-time PCR.

Authors:  D Hardegger; D Nadal; W Bossart; M Altwegg; F Dutly
Journal:  J Microbiol Methods       Date:  2000-06       Impact factor: 2.363

4.  Biologic effects of Mycoplasma pneumoniae and other mycoplasmas from man on hamster tracheal organ culture.

Authors:  A M Collier; W A Clyde; F W Denny
Journal:  Proc Soc Exp Biol Med       Date:  1969-12

5.  Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease.

Authors:  Robert D Hardy; Hasan S Jafri; Kurt Olsen; Jeanine Hatfield; Janie Iglehart; Beverly B Rogers; Padma Patel; Gail Cassell; George H McCracken; Octavio Ramilo
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Epidemiology of Mycoplasma pneumoniae infection in families.

Authors:  H M Foy; J T Grayston; G E Kenny; E R Alexander; R McMahan
Journal:  JAMA       Date:  1966-09-12       Impact factor: 56.272

7.  Elongation factor Tu and E1 beta subunit of pyruvate dehydrogenase complex act as fibronectin binding proteins in Mycoplasma pneumoniae.

Authors:  Shatha F Dallo; T R Kannan; Mark W Blaylock; Joel B Baseman
Journal:  Mol Microbiol       Date:  2002-11       Impact factor: 3.501

8.  Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

Authors:  R D Hardy; H S Jafri; K Olsen; M Wordemann; J Hatfield; B B Rogers; P Patel; L Duffy; G Cassell; G H McCracken; O Ramilo
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

9.  Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice.

Authors:  Hong Wei Chu; Joyce M Honour; Catherine A Rawlinson; Ronald J Harbeck; Richard J Martin
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 10.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more
  19 in total

1.  Fatal outcomes in family transmission of Mycoplasma pneumoniae.

Authors:  T R Kannan; R D Hardy; J J Coalson; D C Cavuoti; J D Siegel; M Cagle; O Musatovova; C Herrera; J B Baseman
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

2.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

3.  Mycoplasma pneumoniae and health outcomes in children with asthma.

Authors:  Pamela R Wood; Jordan C Kampschmidt; Peter H Dube; Marianna P Cagle; Paola Chaparro; Norma S Ketchum; Thirumalai R Kannan; Harjinder Singh; Jay I Peters; Joel B Baseman; Edward G Brooks
Journal:  Ann Allergy Asthma Immunol       Date:  2017-06-19       Impact factor: 6.347

4.  Persistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma.

Authors:  Jay Peters; Harjinder Singh; Edward G Brooks; Joseph Diaz; Thirumalai R Kannan; Jacqueline J Coalson; Janet G Baseman; Marianna Cagle; Joel B Baseman
Journal:  Chest       Date:  2011-05-26       Impact factor: 9.410

5.  Disulfide bond of Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin is essential to maintain the ADP-ribosylating and vacuolating activities.

Authors:  Sowmya Balasubramanian; Lavanya Pandranki; Suzanna Maupin; Kumaraguruparan Ramasamy; Alexander B Taylor; Peter John Hart; Joel B Baseman; Thirumalai R Kannan
Journal:  Cell Microbiol       Date:  2019-05-09       Impact factor: 3.715

6.  Mycoplasma pneumoniae in children with acute and refractory asthma.

Authors:  Pamela R Wood; Vanessa L Hill; Margaret L Burks; Jay I Peters; Harjinder Singh; Thirumalai R Kannan; Shruthi Vale; Marianna P Cagle; Molly F R Principe; Joel B Baseman; Edward G Brooks
Journal:  Ann Allergy Asthma Immunol       Date:  2013-02-23       Impact factor: 6.347

7.  Interleukin-17A Exacerbates Disease Severity in BALB/c Mice Susceptible to Lung Infection with Mycoplasma pulmonis.

Authors:  Maximillion T Mize; Xiangle L Sun; Jerry W Simecka
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

8.  Effect of Qingfei Mixture () on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome.

Authors:  Ai-Jun Yang; Kun Xi; Yan-Qing Yao; Ying-Xue Ding; Li-Jun Yang; Hong Cui
Journal:  Chin J Integr Med       Date:  2017-09-02       Impact factor: 1.978

9.  Functional mapping of community-acquired respiratory distress syndrome (CARDS) toxin of Mycoplasma pneumoniae defines regions with ADP-ribosyltransferase, vacuolating and receptor-binding activities.

Authors:  Thirumalai R Kannan; Manickam Krishnan; Kumaraguruparan Ramasamy; Argentina Becker; Olga N Pakhomova; P John Hart; Joel B Baseman
Journal:  Mol Microbiol       Date:  2014-07-10       Impact factor: 3.501

10.  Mycoplasma pneumoniae CARDS toxin exploits host cell endosomal acidic pH and vacuolar ATPase proton pump to execute its biological activities.

Authors:  Kumaraguruparan Ramasamy; Sowmya Balasubramanian; Alejandra Kirkpatrick; Daniel Szabo; Lavanya Pandranki; Joel B Baseman; T R Kannan
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.